From: The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Clinical endpoint | DDR mutation | ICI | Cancer type | Wild type | Mutation type | Refs |
---|---|---|---|---|---|---|
ORR | BRCA1/2 | Pembrolizumab | Melanoma | 5.0% | 12.0% | [58] |
PRKDC | Anti-CTLA-4 antibody+anti-PD-1 antibody | NSCLC | 32.3% | 66.7% | [68] | |
PRKDC | Anti-CTLA-4 antibody | Metastatic melanoma | 14.6% | 33.3% | [68] | |
DDR mutation | Anti-PD-1/PD-L1 antibodies | Urothelial cancer | 18.8% | 67.9% | [45] | |
PFS | PRKDC | Anti-CTLA-4 antibody+anti-PD-1 antibody | NSCLC | 6.8 m | NR | [68] |
OS | POLE/POLD1 | ICI | Solid tumors | 18.0 m | 34.0 m | [66] |
TP53 + ATM | ICI | NSCLC | 2.8 m–22.0 m | 22.1 m-NR | [67] |